All In Biotech

Drug Trial Radar · NCT07344948

Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

A First in Human, Phase 1/1b Study of Single and Multiple Ascending Dosing Administration of NTX110253 in Healthy Participants and Participants With Stable Schizophrenia

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

73

Planned (sponsor's estimate)

Start

Oct 3, 2025

Primary completion

May 2026

Study completion May 2026

Sponsor

Lead sponsor
NeurosterixIndustry
Sponsor type
Industry
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.

Conditions

  • Healthy Participants
  • Schizophrenia Diagnosis

Interventions

  • NTX-253Drug

    Oral Capsule

  • PlaceboDrug

    Oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of reported Adverse EventsTime frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  2. Number of Adverse Events of Special Interest (AESI)Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  3. Number of dose limiting treatment emergent adverse events (TEAE)Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  4. Vital Signs: Change in blood pressureTime frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  5. Vital Signs: Change in temperatureTime frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  6. Vital Signs: Change in respiratory rateTime frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  7. Vital Signs: Change in heart rateTime frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  8. Change in physical examinationTime frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).
  9. Clinical Laboratory TestsTime frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research, LLC - CenExel

    Los Alamitos, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.